Form Type: 4

SEC EDGAR Link
Accession Number:0000920465-19-000136
Date:2019-09-30
Issuer: LA JOLLA PHARMACEUTICAL CO (LJPC)
Original Submission Date:

Reporting Person:

MULROY DENNIS
C/O LA JOLLA PHARMACEUTICAL COMPANY,
4550 TOWNE CENTRE COURT SAN DIEGO, CA 92121

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2019-09-30 A 213 a $7.48 3,999 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
STOCK OPTION (RIGHT TO BUY) 8.8 2019-09-30 deemed execution date A 213 (a) 2029-09-30 common stock 213 $8.80 213 direct
Footnotes
IDfootnote
f1 these shares were acquired on 09/30/2019 through the la jolla pharmaceutical company 2018 employee stock purchase plan in a transaction that was exempt under both rule 16b-3(d) and rule 16b-3(c).
f2 the stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years.
WhaleWisdom Logo

Elevate your investments